What radiation therapy dose is recommended for non‑Hodgkin lymphoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Radiation Therapy Dose for Non-Hodgkin Lymphoma

For aggressive NHL treated with chemotherapy, use 30 Gy in 15 fractions; for indolent NHL, use 24 Gy in 12 fractions; and for chemorefractory aggressive NHL, use 40-50 Gy in 20-25 fractions. 1

Dose Recommendations by Clinical Scenario

Aggressive NHL (Chemosensitive)

  • Standard dose: 30 Gy in 15 fractions when no significant cardiac/lung exposure or overlapping critical organs 1
  • Alternative: 27 Gy in 9 fractions (3 Gy per fraction) when cardiac/lung exposure or overlapping critical organs present 1

This represents a significant departure from historical doses of 40-45 Gy. The ILROG guidelines from 2020 provide the most current framework, supported by the landmark randomized trial 2 demonstrating no loss of efficacy with 30 Gy compared to 40-45 Gy in aggressive NHL receiving combined modality therapy.

Aggressive NHL (Chemorefractory)

  • 40-50 Gy in 20-25 fractions when no significant cardiac/lung exposure 1
  • Higher doses are necessary because these tumors have demonstrated resistance to systemic therapy

Localized Aggressive NHL (Primary RT Alone - Not Chemo Candidate)

  • 30 Gy in 6 fractions (5 Gy per fraction) when no significant cardiac/lung exposure 1
  • 36-39 Gy in 12-13 fractions (3 Gy per fraction) when cardiac/lung exposure or overlapping critical organs present 1

Indolent Lymphoma (Limited Stage)

  • 24 Gy in 12 fractions as standard dose 1
  • Alternative approach: Start with 4 Gy in 2 fractions, reevaluate after 2-3 months
    • If insufficient response, proceed to definitive RT: 20 Gy in 5 fractions (4 Gy per fraction) 1

The randomized trial 2 confirmed 24 Gy is equally effective as 40-45 Gy for indolent NHL, with overall response rates of 93% vs 92% (p=0.72) and no difference in within-field progression at median 5.6 years follow-up.

Special Subtypes

NK/T-cell lymphoma:

  • 45 Gy in 25 fractions when treated with effective chemotherapy 1
  • Higher doses needed if not treated with chemotherapy or suboptimal regimens

Cutaneous T-cell lymphoma (Total Skin Electron Beam):

  • 10-12 Gy in 6-10 fractions 1
  • Give 2-3 treatments per week, evaluate response after each

Palliative Settings

Symptomatic Aggressive NHL (No Chemo Options)

  • Longer life expectancy: 25 Gy in 5 fractions (5 Gy per fraction) 1
  • Shorter life expectancy: 8 Gy in 1 fraction 1

Symptomatic Indolent Lymphoma

  • Without cord compression: 4 Gy in 1 fraction 1
  • With cord compression: 20 Gy in 5 fractions (4 Gy per fraction) 1

Critical Dose Constraints for Hypofractionation

When using 5 Gy per fraction to 25-30 Gy or 4 Gy per fraction to 36 Gy, maintain these constraints 1:

  • Maximum dose (Dmax) ≤25 Gy for: retina, optic nerves, optic chiasm, cochlea, brainstem, brachial plexus, spinal cord, cauda equina
  • V25 ≤5 cc for: stomach, duodenum, small bowel
  • Mean liver dose ≤20 Gy
  • Mean kidney dose ≤6 Gy (bilateral; optimal if one kidney spared)

If these constraints cannot be met: Use 3 Gy per fraction to 27 Gy for chemosensitive disease or 36 Gy for chemorefractory disease 1

Key Evidence Supporting Dose De-escalation

The randomized phase III trial 2 with 1,001 treatment sites and median 5.6-year follow-up demonstrated:

  • Indolent NHL: No difference in overall response (93% vs 92%, p=0.72) or within-field progression (HR=1.09, p=0.64) between 24 Gy and 40-45 Gy
  • Aggressive NHL: No difference in overall response (91% both arms, p=0.87) or within-field progression (HR=0.98, p=0.89) between 30 Gy and 40-45 Gy
  • Trend toward reduced toxicity with lower doses

Historical data 3 showed all in-field failures in indolent NHL occurred with doses <30 Gy, supporting the 24-30 Gy range. For aggressive NHL with bulky disease (>6 cm) or incomplete response to chemotherapy, doses ≥40 Gy may be beneficial 3.

Common Pitfalls to Avoid

  1. Do not use extended-field or involved-field techniques - Modern practice uses involved-site RT based on PET-defined pre-chemotherapy sites 4, 5

  2. Do not automatically use 40-45 Gy - This historical dose is no longer necessary for most scenarios and increases late toxicity risk 2

  3. Do not ignore organ constraints with hypofractionation - Large fraction sizes increase late effect risk; strict adherence to dose constraints is essential 1

  4. Do not treat bulky chemorefractory disease with low doses - These patients require 40-50 Gy for adequate control 1

References

2
Research

Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2011

4
Research

Recommendations for the use of radiotherapy in nodal lymphoma.

Clinical oncology (Royal College of Radiologists (Great Britain)), 2013

Related Questions

Is urticarial vasculitis associated with lymphoma, particularly B‑cell non‑Hodgkin lymphoma?
In a 78-year-old patient with persistent pruritus, isolated LDH elevation, normal complete blood count, no B symptoms, and a family history of non‑Hodgkin lymphoma, is a contrast‑enhanced CT scan indicated?
In a 78-year-old patient with persistent pruritus, isolated lactate dehydrogenase (LDH) elevation, normal complete blood count, and no B symptoms, does a family history of non-Hodgkin lymphoma (NHL) in a relative diagnosed at age 82 alter the recommended work‑up?
For a patient with a non‑MALT orbital lymphoma recurrence presenting with gross disease, what curative radiation dose should be administered?
A 60-year-old man with a history of non-Hodgkin lymphoma treated in the 1990s presents with weight loss, generalized pruritus, and a vague right axillary mass; what laboratory workup should be performed and what are the next best steps in management?
With a low anion gap and normal serum albumin, what is the appropriate diagnostic work‑up?
If a patient has a normal C‑reactive protein level, can they still have chronic inflammatory demyelinating polyneuropathy (CIDP)?
Can I use graduated compression stockings after a partial hip replacement, and are they a high risk for deep‑vein thrombosis?
I have had a herpes simplex outbreak for three days; should I still start antiviral medication?
What is the appropriate management for a patient with an elevated white blood cell count and herpes simplex virus type 2 infection?
How should pancytopenia be evaluated in a 75-year-old male?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.